靶点- |
作用机制- |
在研机构- |
|
在研适应症- |
|
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期- |
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase Ⅲ Clinical Trial of Yiqi Wenjing Prescriptions for Preventing Oxaliplatin-induced Peripheral Neuropathy
This study is a randomized, placebo-controlled, double-blind, multicenter phase III clinical trial of Yiqi Wenjing prescriptions for Preventing Oxaliplatin-induced Peripheral Neuropathy.
Synergistic Anti-tumor Effect of ChangTai Keli Based on Chemotherapy for Colon Cancer Patients:a Randomized, Parallel-group, Double-blind, Multicenter Clinical Study
The aim of this study is to evaluate the synergistic anti-tumor effect of ChangTai Keli based on chemotherapy for colon cancer patients by a randomized, parallel-group, double-blind, multicenter clinical study.
Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Based on Chemotherapy for Advanced Non-small Cell Lung Squamous Carcinoma Patients:a Randomized Controlled,Open, Multicenter Clinical Study
Explore the efficacy and safety of the treatment of Endostar continuous intravenous injection pump combined DP scheme for first-line advanced lung squamous carcinoma and maintenance treatment., and explore the predicted biomarkers.
100 项与 Nanjing NingQi Medicine Science and Technology Co., Ltd. 相关的临床结果
0 项与 Nanjing NingQi Medicine Science and Technology Co., Ltd. 相关的专利(医药)
100 项与 Nanjing NingQi Medicine Science and Technology Co., Ltd. 相关的药物交易
100 项与 Nanjing NingQi Medicine Science and Technology Co., Ltd. 相关的转化医学